October 31, 2019 10:03 AM EDT
News Briefing

Ab­b­Vie show­cas­es pos­i­tive PhI­II da­ta for Rin­voq; RAPT prices on low end for IPO

Kathy Wong

Editor

→ Ab­b­Vie is tout­ing pos­i­tive da­ta from its SE­LECT-PsA 2 Phase III study of Rin­voq for the treat­ment of pso­ri­at­ic arthri­tis. The study showed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times